Two major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug on their research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central
to R&D conducted by biotechnology Company ProMIS Neurosciences Inc.
(TSX:PMN, OTCQB:ARFXF, Forum).
Preclinical studies show the Company's lead antibody candidate, PMN310,
demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of the toxic oligomer form of
amyloid beta (Aβ).
Not only has an important competitor dropped out of the race to find an Alzheimer’s
treatment, the reason for failure suggests that ProMis is on the right track with its own
research.
Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn
more about ProMIS’ research and potential to combat Alzheimer’s Disease.
Podcast #47 Theralase Technologies
Podcast #46 Molori Energy Inc
Podcast #45: First Majestic Silver – Keith Neumeyer interview
Podcast #44: Wellness Lifestyles Inc
Podcast 43: Molori Energy Inc.
Dr. Guy Chamberland - Tetra Bio-Pharma
Podcast #42. Zomedica Pharmaceuticals Corp
Podcast #41: Luminor Medical Technologies
Podcast #40: PyroGensis Canada
Podcast: #39 Alexandria Minerals
Podcast #38: Canabo Medical
Podcast #37: Deveron UAV
Podcast #36: Vulcan Minerals
Podcast #35: Coro Mining
Dr. Kal Kotecha interviews Peter Clausi
Podcast #34: Brazil Resources
Skyharbour Interview | Mines and Money Podcast
Dr. Kal Kotecha interviews Doug MacQuarrie, CEO at Asante Gold
Dr. Kal Kotecha interviews David Morgan of the Morgan Report
Podcast #33: Neo Lithium
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
U.S Property Podcast
Aligned Money Show
Dubai Property Podcast
The Ramsey Show
The Clark Howard Podcast